OraSure Technologies (Nasdaq: OSUR) reported Q2 2026 net revenue of $30.6 million, down 2% from $31.2 million a year earlier, while diluted EPS improved to $0.09 from a loss of $0.26. Gross margin increased, but the swing to GAAP profitability was primarily driven by a $22.6 million reduction in acquisition-related contingent consideration rather than the underlying operations.
Core Financial Results
Revenue rose 10% sequentially but remained slightly below the prior-year quarter. Core business revenue was essentially unchanged at $30.6 million, while COVID-19 and Risk Assessment Testing revenue fell to almost zero.
Profitability differed sharply between GAAP and non-GAAP measures. GAAP operating income reached $5.4 million, but non-GAAP operating loss widened to $14.7 million, showing that the reported profit largely reflected the contingent consideration remeasurement.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| Net revenue | $30.6 million | $31.2 million | Down 2% |
| GAAP gross profit | $13.3 million | $13.2 million | Up 1% |
| GAAP gross margin | 43.5% | 42.1% | Up 1.4 percentage points |
| GAAP operating income (loss) | $5.4 million | $(18.0) million | Swing to profit |
| Non-GAAP operating loss | $(14.7) million | $(13.2) million | Loss widened by $1.6 million |
| GAAP net income (loss) | $6.2 million | $(19.7) million | Swing to profit |
| Diluted EPS | $0.09 | $(0.26) | Improved by $0.35 |
| Non-GAAP net loss | $(13.8) million | $(14.2) million | Loss narrowed by $0.4 million |
| Non-GAAP diluted EPS | $(0.20) | $(0.19) | Loss increased by $0.01 |
Business and Segment Performance
Diagnostics produced modest growth, supported by higher syphilis revenue and the addition of BioMedomics’ Sickle SCAN sales. Sample Management Solutions remained flat, while declining non-product revenue and the disappearance of Risk Assessment Testing revenue weighed on the consolidated result.
| Revenue category | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| Diagnostics | $19.4 million | $19.2 million | Up 1% |
| Sample Management Solutions | $9.9 million | $9.9 million | Flat |
| Other products and services | $0.5 million | $0.3 million | Up 68% |
| Non-product and services revenue | $0.9 million | $1.4 million | Down 34% |
| COVID-19 Diagnostics | Less than $0.1 million | Less than $0.1 million | Down 96% |
| Risk Assessment Testing | $0 | $0.4 million | Down 100% |
Core revenue, which excludes COVID-19 and Risk Assessment Testing, was $30.638 million compared with $30.768 million a year earlier. This indicates that the continuing portfolio was stable rather than growing materially during the quarter.
Profitability, Cash Flow, and Balance Sheet
Cost of products and services sold declined to $17.3 million from $18.1 million, faster than the decline in revenue. That lifted GAAP gross margin by 1.4 percentage points and non-GAAP gross margin by 1 percentage point to 44.2%.
Underlying operating expenses remained high relative to gross profit. Research and development expense declined to $9.4 million from $11.4 million, but general and administrative expense increased to $14.4 million from $12.7 million. Sales and marketing expense edged up to $6.6 million from $6.4 million.
Cash and cash equivalents were $160.6 million at June 30, 2026, down from $199.3 million at the end of 2025. For the first six months of 2026—not the second quarter alone—OraSure used $23.8 million of operating cash, compared with $30.0 million in the prior-year period. First-half capital expenditures were $3.3 million, stock repurchases used $7.0 million, and foreign exchange reduced cash by another $3.0 million.
OraSure repurchased approximately $2 million of shares during Q2. Cumulative repurchases reached approximately $22 million, or 7.7 million shares, under its $40 million authorization.
A $22.6 Million Remeasurement Drove the GAAP Profit
The quarter’s most important accounting issue was a $22.6 million reduction in the estimated fair value of acquisition-related contingent consideration. The adjustment followed OraSure’s decision to update the submission plan for its InteliQuick CT/NG molecular self-test on the Sherlock platform after receiving FDA feedback.
This non-cash adjustment reduced reported operating expenses and was the principal reason OraSure moved from a GAAP operating loss to operating income. Excluding this and other specified items, the company still recorded a $14.7 million non-GAAP operating loss, wider than the $13.2 million loss a year earlier.
The accounting benefit is also connected to a regulatory delay. In July, OraSure withdrew the current CT/NG submission and said it plans to pursue a future submission. Management said the product’s studies demonstrated strong performance, but the timing and requirements of the next submission were not quantified.
Product and Regulatory Developments
In June, the FDA cleared OraSure’s Colli-Pee Dx Urine Collection Kit for use with Roche tests covering four sexually transmitted infections. The product enables at-home first-void urine collection by male and female patients for testing on Roche’s cobas molecular diagnostics platform.
After the quarter ended, OraSure received FDA Emergency Use Authorization for its second-generation OraQuick Ebola 2.0 Rapid Antigen Test. The test is designed to detect all four Ebola viruses currently known to cause disease in humans. The company did not provide expected revenue contributions from either regulatory milestone.
Guidance
OraSure issued a quantitative revenue outlook for the third quarter of 2026. The range brackets the Q2 revenue level, pointing to a near-term revenue scale broadly similar to the quarter just reported.
| Metric | Latest guidance | Guidance period |
|---|---|---|
| Total revenue | $29.5 million–$32.5 million | Q3 2026 |
No prior Q3 guidance range was provided in the supplied results, so there is no comparable revision to assess.
Management’s View
President and CEO Carrie Eglinton Manner emphasized the 9.7% sequential revenue increase, gross-margin improvement, and recent regulatory milestones as evidence of progress in OraSure’s return-to-growth strategy. Management also said the company’s cash position provides flexibility to invest in innovation and consider targeted collaborations or acquisitions.
However, the year-over-year core revenue result remained flat, and the non-GAAP operating loss shows that revenue growth and expense control still need to improve for the business to reach sustainable operating profitability.
Risks Investors Should Watch
- Underlying operating losses remain substantial: The $5.4 million GAAP operating profit depended on a contingent consideration adjustment, while the non-GAAP operating loss widened to $14.7 million.
- The CT/NG program faces regulatory execution risk: OraSure withdrew its existing submission and plans to submit again after incorporating FDA feedback. Delays or additional development requirements could affect costs and the commercialization timeline.
- Core revenue has yet to establish clear year-over-year growth: Diagnostics increased only 1%, Sample Management Solutions was flat, and total core revenue was essentially unchanged.
- Cash continues to decline: Although the company held $160.6 million in cash, operating activities consumed $23.8 million during the first half, while capital spending, repurchases, and foreign exchange contributed to the overall cash reduction.
- Q3 guidance does not imply a clear acceleration: The $29.5 million to $32.5 million range overlaps Q2 revenue of $30.6 million, leaving continued growth dependent on execution across the core portfolio.
Summary
OraSure’s Q2 2026 results combined improved gross margin and sequential revenue growth with flat year-over-year core revenue and continued non-GAAP operating losses. A $22.6 million contingent consideration remeasurement created the GAAP profit, while the related revision to the Sherlock CT/NG submission plan introduced additional regulatory uncertainty. Investors’ next focus points are the pace of core revenue growth, progress toward reducing underlying losses, cash consumption, and execution within the Q3 revenue range.
Find out more